Role of Estrogen on Skeletal Outcomes in FHA
NCT07010146
This study is recruiting at 2 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to assess whether the natural form of estrogen (17-beta estradiol) given as a patch so that it is absorbed through your skin, is better at improving bone strength over 1 year than natural estrogen (17-beta estradiol) taken by mouth, or a synthetic form oestrogen (ethinyl estradiol) given as a patch that also provides birth control.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Bone Strength
- Bone Density
- FHA (Functional Hypothalamic Amenorrhea)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 14 to 30 years
- Sex
- Female
- Healthy volunteers
- Not accepted
- Sponsor
- University of Virginia
- Last updated on ClinicalTrials.gov
- July 17, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Virginia · 2
- University of Virginia · Charlottesville, VA
- University of Virginia Medical Center · Charlottesville, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.